FMP

FMP

Enter

VCEL - Vericel Corporation

photo-url-https://images.financialmodelingprep.com/symbol/VCEL.png

Vericel Corporation

VCEL

NASDAQ

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

59.56 USD

0.49 (0.823%)

Latest VCEL News

benzinga.com

7 days ago

Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday.

Read More

seekingalpha.com

Dec 19, 2024

Vericel Corporation: Hard To Justify Current Valuation

Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels.

Read More

investors.com

Dec 3, 2024

Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

Read More

zacks.com

Nov 11, 2024

Here's Why Momentum in Vericel (VCEL) Should Keep going

Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Read More

seekingalpha.com

Nov 7, 2024

Vericel Corporation (VCEL) Q3 2024 Earnings Conference Call Transcript

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Burns - Vice President of Finance & Investor Relations Nick Colangelo - Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Mike Kratky - Leerink Partners Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Jeffrey Cohen - Ladenburg Thalmann & Co. Operator Ladies and gentlemen, thank you f...

Read More

zacks.com

Nov 7, 2024

Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.

Read More

globenewswire.com

Nov 7, 2024

Vericel Reports Third Quarter 2024 Financial Results

Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarte...

Read More

globenewswire.com

Oct 24, 2024

Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Read More

globenewswire.com

Aug 29, 2024

Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) --  Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.

Read More

globenewswire.com

Aug 26, 2024

Vericel Announces FDA Approval and Commercial Availability of MACI Arthro

First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultu...

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep